Biolase, Inc.
OOTC:BIOLQ0.00
USD
0.00
(0.00%)
ISIN
US0909117022
CUSIP
090911702
Return %
Stock
S&P 500
1Y
-99.00
14.20
3Y
-100.00
81.12
5Y
-100.00
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Gwang-Bum Park
- Full Time Employees
- 157
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 27042 Towne Centre Drive Lake Forest CA United States 92610-2811
- IPO Date
- Nov 12, 1992
- Website
- biolase.com
- Similar Companies
- Business
- Biolase, Inc. is a medical device company that designs, develops, manufactures, and markets proprietary dental laser systems, consumables, and accessories worldwide. The company operates within the dental equipment and technology sector, providing advanced clinical laser solutions to general dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and dental hygiene specialists across North America, Europe, the Asia-Pacific region, and Latin America. The company's core product portfolio is centered on two primary laser technology platforms: all-tissue laser systems and diode soft-tissue laser systems. Its flagship all-tissue laser systems, marketed under the Waterlase brand (including the Waterlase iPlus and Waterlase Express), utilize patented HydroPhotonic technology that combines water and laser energy to perform hard-tissue, soft-tissue, and bone procedures with minimal thermal damage, reduced trauma, and decreased reliance on local anesthesia; with primary clinical applications encompassing restorative cavity preparation, bone contouring, periodontal pocket debridement, endodontic canal disinfection, and peri-implantitis treatment. Its diode soft-tissue laser systems, commercialized under the Epic brand (including Epic X, Epic Pro, and Epic Hygiene), deliver focused diode laser energy for soft-tissue surgical incisions, coagulation, hemostasis, photobiomodulation for temporary pain relief, and laser-assisted in-office tooth whitening. Biolase also sells proprietary consumables and auxiliary products, including single-use and reusable laser tips, specialized handpieces, optical fibers, protective eyewear, and cosmetic whitening kits; and offers technical support, extended maintenance warranties, and professional clinical training certifications through its educational divisions. Founded in 1984 and headquartered in Lake Forest, California, with primary manufacturing operations located in Corona, California, the company distributes its products through a combination of direct sales forces and independent international distributors. In October 2024, Biolase initiated voluntary Chapter 11 bankruptcy proceedings in the United States, culminating in a November 2024 court-supervised asset sale under Section 363 of the U.S. Bankruptcy Code in which South Korea-based dental manufacturer MegaGen Implant Co., Ltd. acquired substantially all of Biolase's operating assets for approximately $20.05 million. Following the transaction, Biolase operates as a MegaGen company, while its legacy equity trades on the Over-the-Counter market under the ticker symbol BIOLQ. Under MegaGen's ownership, the business has undertaken operational restructuring and capital investment initiatives, including cleanroom modernizations and production capacity upgrades at its California manufacturing facility, to enhance product supply stability, advance research and development in all-tissue laser systems, and expand global commercial distribution.